References Hayashi, D., Edwards, C., Emond, J
Although not readily used in the UK due to ongoing regulatory ambiguities, they are increasingly prescribed in other countries and subject to intensive ongoing research
Each batch undergoes comprehensive testing including HPLC for purity, heavy metal analysis, microbial testing, and stability assessment
This triple-action mechanism produces significantly greater fat loss, appetite suppression, and metabolic improvement compared to older medications
Semaglutide 2.4mg (Wegovy) is commissioned by the NHS only through specialist weight management services, with specific eligibility criteria (including BMI thresholds, which are lower for people from some ethnic groups) and a maximum treatment duration of 2 years